We evaluated the contributions of various polyglutamine (polyQ) disease genes to Yamashita C et al., Page 3 Parkinson's disease (PD). We compared the distributions of polyQ repeat lengths in eight common genes (ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, TBP, ATN1, and 40 HTT) in 299 unrelated patients with autosomal dominant PD (ADPD) and 329 normal controls. We also analyzed the possibility of genetic interactions between ATXN1 and ATXN2, ATXN2 and ATXN3, and ATXN2 and CACNA1A. Intermediate-length polyQ expansions (>24 Qs) of ATXN2 were found in seven ADPD patients and no controls (7/299 = 2.34% and 0/329 = 0%, respectively; P = 0.0053 < 0.05/8 after Bonferroni 45 correction). These patients showed typical L-DOPA-responsive PD phenotypes.
Introduction
Several genes other than the "PARK" genes are suspected to be responsible for parkinsonism. Mutations of these genes sometimes confer symptoms that clinically 55 mimic idiopathic Parkinson's disease (PD) and present radiological or pathological findings characteristic of PD (Klein, et al., 2009) . These genes include the polyglutamine (polyQ) disease genes: HTT (Walker, 2007) , ATXN1 (Dubourg, et al., 1995) , ATXN2 (Charles, et al., 2007 ,Furtado, et al., 2004 ,Gwinn-Hardy, et al., 2000 , ATXN3 (Lu, et al., 2004a ,Subramony, et al., 2002 , CACNA1A (Kim, et al., 2010) , and 60 TBP (Kim, et al., 2009) . Of these genes, it has been suggested that intermediate-length polyQ expansions in ATXN2 and TBP are associated with PD (Charles, et al., 2007 ,Furtado, et al., 2004 ,Kim, et al., 2009 ).
In addition, intermediate-length polyQ expansions (24-33 Qs) in ATXN2 have recently been suggested as a risk factor for amyotrophic lateral sclerosis (ALS) (Chen, conditions are described in Supplementary Table e1 . The PCR products were mixed 95 with the LIZ-500 size standard (Applied Biosystems, Foster City, CA) and processed on an Applied Biosystems 3130 Genetic Analyzer (Applied Biosystems) for size determination. The sizes of the repeats were determined with GeneMapper™ 3.7 software (Applied Biosystems).
Statistical analysis was performed using JMP 8 software (SAS Institute, Cary, NC).
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We evaluated the association between ADPD and the polyQ repeat lengths of each gene using two-tailed Fisher's exact tests, as previously described (Gispert, et al., 2012 ,Lee, et al., 2011a ,Ross, et al., 2011 . A P value < 0.05/8 after Bonferroni correction wasconsidered significant (8 is for the number of genes investigated in the current study.). 
Results

Molecular Genetic Analysis
The range of repeat lengths in ATXN2 was between 19 and 35. The majority of patients (95.6% of patients with ADPD and 98.6% of the controls) had a repeat length of 22, as reported in previous studies (Lee, et al., 2011a ,Pulst, et al., 1996 . Of the 253 110 patients with ADPD, 7 harbored repeat lengths longer than 24, whereas none of the controls did (2.8% and 0%, respectively; P=0.0053, Figure 1 and Table 1 ).
No substantial differences in the repeat lengths in ATXN1, ATXN3, CACNA1A, ATXN7, TBP, ATN1, or HTT were observed between the ADPD patients and controls (Table 1 and Supplementary Figure e1) . 115 We supplementarily sequenced entire coding exons and exon/intron boundaries of glucocerebrosidase gene (GBA) in the 7 probands with intermediate ATXN2 polyQ expansion, because rare GBA mutations have been considered to be a risk factor for PD (Li, et al., 2013 ,Mitsui, et al., 2009 ; no GBA mutation was found in these 7 probands. Table e2 ). All of these signs were relieved by pramipexole. AIII-3 was reportedly initially diagnosed with essential tremor because her first sign was bilateral postural tremor. She underwent left and right thalamotomy at a one-year interval. She showed hyperreflexia in the lower extremities, but this symptom was presumably due to cervical spondylosis, for which surgical decompression was performed. AIV-2 and AIV-3, who inherited an intermediate-length polyQ expansion of 35 Qs, were not affected at the time of this study.
In Family B, BI-2 was affected at an older age than her offspring, although their genotypes were the same, and all had L-DOPA-responsive parkinsonism with laterality 135 (Supplementary Table e2 ).
In Family C, CII-2 was diagnosed with Parkinson's disease with dementia. Although her parents were consanguineous, her polyQ ATXN2 lengths were heterozygous (29/22).
All other members of the seven families showed L-DOPA-responsive parkinsonism 140 with laterality and were free of motor neuron signs, cerebellar ataxia, and saccadic eye movement disorder. None was reported to have any significant brain magnetic resonance imaging (MRI) abnormality (Supplementary Table e2 ).
Discussion
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We investigated the distributions of the polyQ repeat lengths of eight common polyQ disease genes (ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, TBP, ATN1, and HTT) in patients with ADPD. PolyQ repeat lengths > 24 in ATXN2 were significantly more common in the patients than in the controls. To the best of our knowledge, there have been only two similar studies investigating the distribution of ATXN2 polyQ repeat 150 lengths in PD patients and controls to date (Gispert, et al., 2012 ,Ross, et al., 2011 .
Although both previous studies failed to prove any significant difference, one (Gispert, et al., 2012) showed that PD patients tended to have longer repeat lengths, consistent with our results. In the other previous study (Ross, et al., 2011) , the controls might have included some number of pre-symptomatic patients because the mean age of the 155 controls was lower than that of the PD patients.
In reference to the recent studies concerning the effect of polyQ repeat length on neurodegenerative disease, we screened for a threshold of the normal ATXN2 polyQ repeat length around a range from 24 to 34 (Charles, et al., 2007 ,Chen, et al., 2011 ,Elden, et al., 2010 ,Gispert, et al., 2012 ,Lee, et al., 2011a ,Lee, et al., 2011b ,Ross, 160 et al., 2011 . The distribution of our patients differed significantly from that of controls only when the cutoff was set to 25. This may be much lower than the threshold for ATXN2-related PD adopted by previous studies (Charles, et al., 2007) , but it is possible that the cutoff for ATXN2 polyQ repeat length and its influence on PD may vary from population to population, as is the case for ALS, as indicated in a previous study (Lee, populations (Charles, et al., 2007 ,Klein, et al., 2009 ,Lu, et al., 2004b ,Sun, et al., 2011 ,Wang, et al., 2009 . Additional factors, such as cis-and trans-acting genetic elements, non-allelic genetic modifiers, and stochastic and environmental factors 170 (Charles, et al., 2007 ,Pulst, et al., 2005 , might have enhanced the toxicity of ATXN2 intermediate-length polyQ expansion in our population.
We described the details of family members with ATXN2 intermediate-length expansions (> 24 Qs, Figure 2 and Supplementary Table e2 ). These patients generally manifested typical PD phenotypes without motor neuron signs, cerebellar ataxia, or 175 saccadic eye movement disorder, as was stated in previous reports (Furtado, et al., 2004 ,Klein, et al., 2009 . A correlation between the association of AAO and polyQ repeat length was not clearly present or absent in our patients with repeat lengths of ATXN2 > 24, as previously observed (Furtado, et al., 2002 ,Furtado, et al., 2004 ,Payami, et al., 2003 ,Sun, et al., 2011 . For example, in Family A, members of the 3 rd generation 180 had earlier AAOs than did their mother. However, there was a gap between the AAOs of AIII-1 and AIII-3, even though their genotypes were the same. In addition, AIII-1 and AIII-3 had two allele expansions (35/32 Qs) instead of a single allele expansion, which might have caused their early onsets (Ragothaman, et al., 2004) . The 35Q alleles may have been inherited 'as is' from AII-1, who reportedly had no neurological disorder, although it is also possible that an expansion occurred upon transmission.
Thus, AAOs might be affected by features other than polyQ repeat length, such as genetic and epigenetic factors.
In the current study, we did not find any association between the ADPD phenotype and the repeat lengths of polyQ disease genes other than ATXN2. This result implies 190 that the contribution of ATXN2 to ADPD is due to the specific effects of this gene rather than the presence of the polyQ expansion itself, as reported in a previous study of ALS (Lee, et al., 2011a) . This result might appear to be inconsistent with recent reports suggesting that the intermediate polyQ expansion of TBP is likely to be a risk factor for PD (Kim, et al., 2009 ,Wu, et al., 2004 ,Xu, et al., 2010 ,Yun, et al., 2011 However, because those reports did not provide significant evidence, and because all of these studies were performed in East Asian patients, further evidence should be accumulated.
As a supplementary analysis, we also applied a multiple logistic regression including the product terms ATXN1*ATXN2, ATXN2*ATXN3, and ATXN2*CACNA1A in order to 200 screen for some interactions among these polyQ disease gene combinations, based on previous studies showing the possibility of interaction among these polyQ genes (Al-Ramahi, et al., 2007 ,Jardim, et al., 2003 ,Lessing and Bonini, 2008 The histogram shows only subjects with ≥ 23 repeats.
Figure 2
The pedigrees of 7 families in which the proband has an ATXN2 polyQ repeat length > 24.
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ATXN2 repeat lengths are listed above and to the right of the pedigree symbols of the genotyped individuals. 
